These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9801503)

  • 41. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 44. Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient.
    Bradley RR; Cunniff PJ; Pereira BJ; Jaber BL
    Am J Kidney Dis; 1999 Aug; 34(2):349-54. PubMed ID: 10430986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
    Glaspy J; Cavill I
    Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
    Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
    Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
    [No Abstract]   [Full Text] [Related]  

  • 48. Case management of the anemic patient. Epoetin alfa: focus on hematocrit.
    Kirlin L
    ANNA J; 1992 Feb; 19(1):66-7. PubMed ID: 1546890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.
    Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P
    Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152
    [No Abstract]   [Full Text] [Related]  

  • 50. Current perspectives: iron management during therapy with recombinant human erythropoietin.
    York S
    ANNA J; 1993 Dec; 20(6):645-50; quiz 651-2. PubMed ID: 8267408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erythropoietin 1991--an overview.
    Eschbach JW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tools for analyzing trends in anemia management case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2000 Feb; 27(1):57-60. PubMed ID: 10852692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in anemia at initiation of dialysis in the United States.
    Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
    Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T; Ogawa H; Saito A; Ito A
    Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
    Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of recombinant human erythropoietin (rHuEpo) in humans.
    Adamson JW; Eschbach JW
    Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
    Cotter DJ; Thamer M; Kimmel PL; Sadler JH
    Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
    Wiecek A; Kokot F; Grzeszczak W; Klin M
    Pol Tyg Lek; 1990 Sep 17-24; 45(38-39):782-6. PubMed ID: 2095546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.